Openbookopenbook
Equity
biote Corp(BTMD)
USD --+0.00%
Reward75High
Risk48Moderate
📊75%Data
Revenue down 7% YoY
BTMD
+0.0 · +0.00%
USD · NASDAQ
biote Corp | Healthcare
Quality Compounder
Market Cap:82.73M
ℹ️
Reward Rating
75
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
48
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BTMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $2.97.

What is biote Corp?

operates in practice-building business within the hormone optimization space.

BTMD · Verdict

Strong reward · moderate risk

BTMD stands out on valuation and profitability, but watch the volatility signal.

Based on 88% data coverage

BTMD · Verdict

What’s working & what to watch

Strengths 4

  • Valuation100/100

    P/E 4.7× · PEG 0.22

  • Profitability88/100

    14% net margin · 0% ROE

  • Cash flow87/100

    16% free-cash-flow margin

  • Growth75/100

    Revenue +5.2% CAGR

Watchouts 2

  • Volatility35/100

    Below average

  • Balance sheet43/100

    Interest covered 3.2×

Model-based scoring. For information only — not financial advice.

What is biote Corp?

operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 82.73M, and a P/E ratio of 3.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (75)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap82.73M
P/E Ratio3
Dividend YieldN/A
52 Week High4.7498
52 Week Low1.27
Last AnnualDecember
IPO Date4/28/2021
IncorporatedUSA
Shares Outstanding32M
No. of Employees223
IndustryMedical Care Facilities
ExchangeNASDAQ
Beta1.291
CurrencyUSD
Websitewww.biote.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.